Optiver Holding
HOWL icon

Optiver Holding’s Werewolf Therapeutics HOWL Stock Holding History

Optiver Holding’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8 Hold
22
– – ﹤0.01% 2735
2026
Q1 		$18 Hold
22
– – ﹤0.01% 2272
2025
Q4 		$14 Hold
22
– – ﹤0.01% 2421
2025
Q3 		$43 Buy
+22
New +$30 ﹤0.01% 2624

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Optiver Holding's HOWL Position: Q2 2026 in Review

Optiver Holding held its Werewolf Therapeutics (HOWL) position steady in Q2 2026 at 22 shares worth $8. The position accounts for ﹤0.01% of the portfolio, ranked #2735.

Optiver Holding first reported a position in HOWL in Q3 2025 and has held it in 4 quarters since. The position peaked at $43 in Q3 2025. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • Optiver Holding held 22 shares of Werewolf Therapeutics worth $8 as of Q2 2026.
  • Optiver Holding left its Werewolf Therapeutics share count unchanged in Q2 2026.
  • Werewolf Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2735 holding.
  • Optiver Holding first reported a position in Werewolf Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Optiver Holding's Werewolf Therapeutics position peaked at $43 in Q3 2025.
  • 45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.